Sam A Pharm Co Stock Revenue

009300 Stock  KRW 17,310  240.00  1.37%   
Sam A Pharm Co fundamentals help investors to digest information that contributes to Sam A's financial success or failures. It also enables traders to predict the movement of Sam Stock. The fundamental analysis module provides a way to measure Sam A's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sam A stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Sam A Pharm Co Company Revenue Analysis

Sam A's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Revenue

 = 

Money Received

-

Discounts and Returns

More About Revenue | All Equity Analysis

Current Sam A Revenue

    
  54.67 B  
Most of Sam A's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sam A Pharm Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Competition

Based on the latest financial disclosure, Sam A Pharm Co reported 54.67 B of revenue. This is much higher than that of the Healthcare sector and significantly higher than that of the Pharmaceuticals industry. The revenue for all Republic of Korea stocks is significantly lower than that of the firm.

Sam Revenue Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sam A's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sam A could also be used in its relative valuation, which is a method of valuing Sam A by comparing valuation metrics of similar companies.
Sam A is currently under evaluation in revenue category among its peers.

Sam Fundamentals

About Sam A Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Sam A Pharm Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sam A using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sam A Pharm Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Pair Trading with Sam A

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sam A position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sam A will appreciate offsetting losses from the drop in the long position's value.

Moving together with Sam Stock

  0.81102940 Kolon Life SciencePairCorr
  0.88074430 Aminologics CoLtdPairCorr

Moving against Sam Stock

  0.35216080 JETEMAPairCorr
The ability to find closely correlated positions to Sam A could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sam A when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sam A - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sam A Pharm Co to buy it.
The correlation of Sam A is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sam A moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sam A Pharm moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sam A can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in Sam Stock

Sam A financial ratios help investors to determine whether Sam Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sam with respect to the benefits of owning Sam A security.